Korro Bio, Inc.

Todd Chappell, our Chief Operating Officer, will highlight Korro’s OPERA™ platform at RNA Leaders USA Congress on Thursday, September 5, at 9:05 AM PT. The presentation, “Developing Novel RNA Editing Therapies to Address Unmet Needs for Rare and Highly Prevalent Diseases,” will discuss OPERA’s potential for creating transformative genetic medicines for diseases of the liver, CNS, and beyond. To learn more about the Congress agenda, visit https://lnkd.in/e87H8A5H #KorroBio #RNALeaders #RNAediting #BiotechInnovation

We are pleased to announce that Jeffrey Cerio, Pharm.D, J.D., was appointed as SVP, General Counsel for Korro.     Jeff joins us with extensive experience in guiding life sciences companies through pivotal growth phases. His expertise includes leading and advising companies on various legal matters relating to corporate governance, business development, financing, securities law, compliance and intellectual property. At Korro, Jeff will oversee all legal aspects of the company’s operations and provide guidance and support as we advance our pipeline programs for both rare and highly prevalent diseases. Please join us in welcoming Jeff to Korro!   #KorroBio #BiotechLeadership

Come and be part of this excited newly formed clinical team!

Korro’s Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director. With over 25 years in the pharmaceutical and biotech industries, Dr. Knobil has played a pivotal role in advancing numerous therapeutics from early-stage development to regulatory approval and commercialization. With her guidance, we are poised to advance our pipeline of innovative programs and further strengthen our commitment to top-tier clinical and regulatory excellence. Read the full release: https://lnkd.in/gxgpziwM

Korro’s leadership team will participate in the upcoming September scientific and investor conferences.   Wells Fargo Healthcare Conference (Wednesday, September 4): CEO and President Ram Aiyar, Ph.D., and CFO Vineet Agarwal will participate in 1x1 investor meetings.   RNA Leaders USA Congress (Thursday, September 5): COO Todd Chappell, will discuss the benefits of our OPERA™ platform in a presentation, “Developing Novel RNA Editing Therapies to Address Unmet Needs for Rare and Highly Prevalent Diseases” at 9:05 AM ET.   H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference (Monday, September 9): Dr. Aiyar will present at 12:30 PM ET, with CFO Vineet Agarwal also in attendance.   ISCTM 2024 Autumn Conference (Thursday, September 12): CMO Kemi Olugemo, MD, FAAN, will be chairing the session, “Use of neurophysiological markers to design and enrich clinical trials in rare neurological disorders” at 8:30 AM ET.   Read the full release here: https://lnkd.in/eGSe9dHz   #KorroBio #WellsFargo #RNALeaders #HCWainwright #ISCTM #BiotechInnovation

Korro Bio welcomes Julie K. Hagan, MS as Vice President of Regulatory Affairs.   Julie brings 20 years of experience in Regulatory Affairs, with expertise in AAV gene therapies, autologous cell therapies, CRISPR gene editing, LNP delivery, and monoclonal antibodies.   Julie will play a pivotal role in Korro’s growing clinical team, overseeing regulatory strategy, operations, and compliance across all of our programs. Her leadership will be instrumental as we navigate the next stages of development and regulatory approval for our innovative therapies.   Please join us in welcoming Julie to the #KorroKrew!   #KorroBio #RegulatoryAffairs #AAVGeneTherapies

We are pleased to welcome Caroline O'Hara to our growing clinical team as Vice President of Clinical Operations! Caroline brings over 20 years of experience in clinical operations within the life sciences industry, with a recent focus on #RareDiseases and #GeneTherapy. Her expertise in the development and launching of clinical trials will be instrumental as we prepare for KRRO-110's entry into the clinic. Join us in welcoming Caroline to the #KorroKrew! #KorroBio #ClinicalOperations

Korro is proud to sponsor the Life Science Cares Boston Mini Golf for Good tournament on September 18th at Tech Square.   Our team is looking forward to a day of fun as we tee off with 600+ life science professionals. We’re putting for a great cause and making a difference in Greater Boston. See you on the green! ⛳

Today, we reported our second quarter 2024 financial results and recent progress. Korro remains on track for regulatory filing of our first-in-human study of KRRO-110 for the potential treatment of #AATD, anticipated in 2H'24. Our strong cash position provides runway into 2H'26 to fund multiple value-creating milestones, including the anticipated completion of the KRR0-110 FIH trial and progression of additional pipeline candidates. Read the full press release here: https://lnkd.in/eCRZQemg #KorroBio